Amgen faces safety concerns over its rare disease therapy Tavneos, with patient deaths in Japan prompting prescription restrictions and potential U.S. withdrawal. Despite near-term volatility, the stock has strong long-term returns (27.83% one-year, 70.14% three-year). A new CFO was appointed, and analysts see potential 30% upside. Current share price is $337.42.